treatments

Surgical treatment is generally reserved for single or multiple tumors located in the same liver segment and for patients with preserved liver function without clinically significant portal hypertension. The treatment and personalized care plan (PCP) will be outlined to the patient during a dedicated pre-surgery consultation. Patient selection for surgery depends on several factors such as underlying liver function, remaining liver volume, and the presence or absence of portal hypertension. Patients must undergo a series of preoperative tests to assess their health status and suitability for surgery based on these criteria.

The primary goal of surgical treatment is to completely remove the cancerous tumor while preserving remaining liver function. New techniques, including laparoscopy, allow for less invasive surgery, with faster recovery and fewer postoperative complications. Laparoscopy is a minimally invasive surgical technique that uses thin instruments and a small tube equipped with a camera to view the inside of the body. This technique allows for more precise and less invasive surgery for patients with hepatocellular carcinoma.

Side effects of surgery may include postoperative pain, fatigue, loss of appetite, nausea and vomiting, and decompensation of cirrhosis. Post-treatment monitoring is important to detect any recurrence or recurrence of the tumor. Patients will be followed regularly by their primary care physician, and imaging tests, such as CT scans or MRIs, will be performed every 3 months to monitor the progression of the disease.

In conclusion, surgery is an effective treatment option for patients with hepatocellular carcinoma presenting with one or more lesions located in the same segment of the liver but reserved for patients with preserved liver function and in the absence of significant portal hypertension. New techniques such as laparoscopy allow for less invasive surgery with faster recovery and fewer postoperative complications.

Surgical treatment is generally reserved for single or multiple tumors located in the same liver segment and for patients with preserved liver function without clinically significant portal hypertension. The treatment and personalized care plan (PCP) will be outlined to the patient during a dedicated pre-surgery consultation. Patient selection for surgery depends on several factors such as underlying liver function, remaining liver volume, and the presence or absence of portal hypertension. Patients must undergo a series of preoperative tests to assess their health status and suitability for surgery based on these criteria.

Radioembolization treatment is generally reserved for single tumors, not amenable to treatment by surgery, ablation, or chemoembolization, and for patients with preserved liver function. This treatment may also appear as a waiting treatment before surgery or liver transplantation. The treatment and personalized care plan (PCP) will be presented to the patient during a dedicated consultation during the MTR.

Radioembolization is an interventional radiology technique performed by a radiologist that takes place in two stages: The first stage is the preparatory phase. In interventional radioligy, a catheter is introduced into the femoral artery, located at the root of the thigh, or through the radial artery located at the wrist, and then directed towards the hepatic artery. Once the catheter is positioned near the tumor, the radiologist checks the tumor vascularization and injects the preparation based on micro-aggregates of radioactive albumin into the tumor. The product, non-toxic, makes it possible to verify the good fixation of the product at the tumor level and the absence of fixation outside the tumor at the liver level and the absence of fixation elsewhere in the body. The patient is then transferred to nuclear medicine to undergo a scintigraphy. This examination is painless. The second stage is the therapeutic phase which will take place in a similar way to the preparatory phase unlike the injection of radioactive beads. This intervention is performed under local anesthesia.

Radioembolization can be performed as a short-term inpatient procedure, usually for 2-3 days per treatment phase, or as an outpatient procedure depending on the center. The procedure may be associated with side effects such as nausea, fatigue, and mild abdominal pain. These side effects are usually temporary and can be managed with medication or symptomatic treatments. Post-treatment monitoring helps assess treatment response. Patients will be followed regularly by their primary care physician, and imaging tests, such as CT scans or MRIs, will be performed every 3 months to monitor disease progression. The true effectiveness of the treatment is generally assessed approximately 6 months after treatment due to the prolonged action of the radiation.

In conclusion, radioembolization is an effective treatment option for patients with hepatocellular carcinoma not amenable to surgery, ablation, or chemoembolization, which allows direct targeting of cancer cells in the liver with minimal side effects. Note that this technique is not indicated in patients with: - Unpreserved liver function; - Renal failure; - Extrahepatic metastases; - Major heart failure; - Certain blood test abnormalities.

Chemoembolization treatment is generally reserved for multiple tumors, not amenable to surgical or ablation treatment, and for patients with preserved liver function. This treatment may also appear as a waiting treatment before surgery or liver transplantation. The treatment and personalized care plan (PCP) will be presented to the patient during a dedicated consultation during the multidisciplinary meeting.